The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

BACKGROUND: Anthracycline/cyclophosphamide-taxane-containing chemotherapy (AC-T) is the standard of care in the adjuvant treatment of HER2-negative early breast cancer (EBC), but recent studies suggest omission of anthracyclines for reduced toxicity without compromising efficacy. METHODS: Based on i...

Descripción completa

Detalles Bibliográficos
Autores principales: de Gregorio, Amelie, Janni, Wolfgang, Friedl, Thomas W. P., Nitz, Ulrike, Rack, Brigitte, Schneeweiss, Andreas, Kates, Ronald, Fehm, Tanja, Kreipe, Hans, Christgen, Matthias, Kümmel, Sherko, Trapp, Elisabeth, Wuerstlein, Rachel, Hartkopf, Andreas, Clemens, Michael, Reimer, Toralf, Häberle, Lothar, Fasching, Peter A., Gluz, Oleg, Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174181/
https://www.ncbi.nlm.nih.gov/pubmed/35194193
http://dx.doi.org/10.1038/s41416-021-01690-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174181/
https://www.ncbi.nlm.nih.gov/pubmed/35194193
http://dx.doi.org/10.1038/s41416-021-01690-6

Ejemplares similares